Skip to main content
SpringerLink
Log in

Antibiotic Resistance and Implications for the Appropriate Use of Antimicrobial Agents

  • Chapter
Book cover Management of Antimicrobials in Infectious Diseases

Part of the book series: Infectious Disease ((ID))

Abstract

The development of antibiotics completely revolutionized medicine in the second half of the 20th century. By 1940, the team researching penicillin recognized that its discovery was a monumental event. Fearing Hitler’s invasion of Great Britain, they rubbed spores of Penicillium notatum into their coat linings to ensure that the mold would go with them in the event they had to escape rapidly (1). In the more than 60 years since its discovery, penicillin has evolved from being a miraculous cure for infectious disease to being a small part of an arsenal of antimicrobial drugs. With the expansion of antibiotic therapy, hygiene, and sanitation in the United States, mortality due to infectious diseases has dropped markedly over the 20th century (2–4). Since 1982, however, deaths attributable to infectious diseases have begun to climb (3) and this rise has occurred in parallel with increased antibiotic resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Radestsky M. The discovery of penicillin. Pediatr Infect Dis J 1996; 15: 811–818.

    Article  Google Scholar 

  2. Centers for Disease Control and Prevention. Control of infectious diseases. MMWR 1999; 48: 621–629.

    Google Scholar 

  3. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: 61–66.

    Article  PubMed  CAS  Google Scholar 

  4. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, Berkelman RL. Trends in infectious disease mortality in the United States. JAMA 1996; 275: 189–193.

    Article  PubMed  CAS  Google Scholar 

  5. Stephenson J. Icelandic researchers are showing the way to bring down rates of antibiotic-resistant bacteria. JAMA 1996; 275: 175.

    Article  PubMed  CAS  Google Scholar 

  6. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999; 96: 1152–1156.

    Article  PubMed  CAS  Google Scholar 

  7. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233–1237.

    Article  PubMed  CAS  Google Scholar 

  8. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337: 441–446.

    Article  PubMed  Google Scholar 

  9. Chen DK, McGeer A, De Azavedo JC, Low DE, The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233–239.

    Article  PubMed  CAS  Google Scholar 

  10. Levy SB. Antibiotic resistance: an ecological imbalance. Ciba Foundation Symposium 1997; 207:1–9. discussion 9–14.

    Google Scholar 

  11. Abraham EP, Chain E Enzyme from bacteria able to destroy penicillin. Nature 1940; 146: 837.

    CAS  Google Scholar 

  12. Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA 1996; 275: 300–304.

    Article  PubMed  CAS  Google Scholar 

  13. Centers for Disease Control and Prevention. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR 1996; 45: 1–20.

    Google Scholar 

  14. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46: 1–25.

    Google Scholar 

  15. Centers for Disease Control and Prevention. Geographic variation in penicillin resistance in Streptococcus pneumoniae-selected sites, United States, 1997. MMWR 1999; 48: 656–661.

    Google Scholar 

  16. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network, Streptococcus pneumoniae, 1998. http://www.cdc.gov/ncidod/dbmd/abcs.

    Google Scholar 

  17. World Health Organization World malaria situation in 1994, part 1. Wkly Epidemiol Rec 1997; 72: 269–276.

    Google Scholar 

  18. Centers for Disease Control and Prevention. Malaria surveillance-United States, 1995. MMWR 1999; 48: 1–23.

    Google Scholar 

  19. Barat LM, Bloland PB. Drug resistance among malaria and other parasites. Infect Dis Clin North Am 1997; 11: 969–987.

    Article  PubMed  CAS  Google Scholar 

  20. Centers for Disease Control and Prevention. Health information for international travel, 1999–2000. Atlanta, GA: Department of Health and Human Services, 1999.

    Google Scholar 

  21. Bjorkman A, Phillips-Howard PA. The epidemiology of drug-resistant malaria Trans R Soc Trop Med Hyg 1990; 84: 177–180.

    Article  CAS  Google Scholar 

  22. Krogstad DJ. Malaria as a reemerging disease. Epidemiol Rev 1996; 18: 77–89.

    Article  PubMed  CAS  Google Scholar 

  23. Olliaro P, Cattani J, Wirth D. Malaria, the submerged disease. JAMA 1996; 275: 230–233.

    Article  PubMed  CAS  Google Scholar 

  24. Centers for Disease Control and Prevention. Tuberculosis morbidity-United States, 1997. MMWR 1998; 47: 253–257.

    Google Scholar 

  25. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. N Engl J Med 1998; 338: 1641–1649.

    Article  PubMed  Google Scholar 

  26. Centers for Disease Control and Prevention. Progress toward the elimination of tuberculosis-United States, 1998. MMWR 1999; 48: 732–736.

    Google Scholar 

  27. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1065–1078.

    Article  PubMed  CAS  Google Scholar 

  28. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527–533.

    Article  PubMed  CAS  Google Scholar 

  29. D’ Aquila RT, Johnson VA, Welles SL, Japour AI, Kuritzkes DR, DeGruttola V, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401–408.

    Article  PubMed  Google Scholar 

  30. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. JAMA 1998; 280: 78–86.

    Article  PubMed  CAS  Google Scholar 

  31. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091–1098.

    Article  PubMed  CAS  Google Scholar 

  32. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000; 90: 223–229.

    Article  PubMed  CAS  Google Scholar 

  33. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HIV seroprevalence. Clin Infect Dis 1999; 29: 321–327.

    Article  PubMed  CAS  Google Scholar 

  34. Kleiman MB, Weinberg GA, Reynolds JK, Allen SD. Meningitis with beta-lactam-resistant Streptococcus pneumoniae: the need for early repeat lumbar puncture. Pediatr Infect Dis J 1993; 12: 782–784.

    Article  PubMed  CAS  Google Scholar 

  35. Lonks JR, Durkin MR, Meyerhoff AN, Medeiros AA. Meningitis due to ceftriaxone-resistant Streptococcus pneumoniae. N Engl J Med 1995; 332: 893–894.

    Article  PubMed  CAS  Google Scholar 

  36. Catalan MJ, Fernandez JM, Vazquez A, Varela de Seijas E, Suarez A, Bernaldo de Quirós JCL. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis 1994; 18: 766–769.

    Article  PubMed  CAS  Google Scholar 

  37. Friedland IR, McCracken GH. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377–382.

    Article  PubMed  CAS  Google Scholar 

  38. Wise R. Science, medicine, and the future: the development of new antimicrobial agents. Br Med J 1998; 317: 643–644.

    Article  CAS  Google Scholar 

  39. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliot MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282: 31–35.

    Article  PubMed  CAS  Google Scholar 

  40. The MIST (Management of Influenza in the Southern Hemisphere) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877–1881.

    Article  Google Scholar 

  41. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permante efficacy trial. Abstract 38th ICAAC, San Diego, California, September 24–27, 1998; 8–9.

    Google Scholar 

  42. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1994; 44: 1–13.

    Google Scholar 

  43. Dowell SF, Marcy SM, Phillips WR, Gerber MA, Schwartz B. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pediatrics 1998; 101: 163–165.

    Google Scholar 

  44. U.S. Food and Drug Administration. Center for Vetrinary Medicine. Guidence for industry #78. Consideration of the human health impact of the microbial effects of antimicrobial new animal drugs intended for use in food-producing animals. Dec. 13, 1999. www.fda.gov/cvm/fda/TOCS/ guidad78.html.

  45. US Food and Drug Administration, Center for Veterinary Medicine. A proposed framework for evaluating and assuring the human safety of the microbial effects of antimicrobial new animal drugs intended for use in food-producing animals. Jan 6, 1999. www.fda.gov/cvm/fda/infores/vmac/antim18.htm.

  46. Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 1991; 324: 601–612.

    Article  PubMed  CAS  Google Scholar 

  47. Shlaes DM, Gerding DN, John JF, Craig WA, Bornstein DL, Duncan RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584–599.

    Article  PubMed  CAS  Google Scholar 

  48. Hawkey PM. The origins and molecular basis of antibiotic resistance. Br Med J. 1998; 317: 657–660.

    Article  CAS  Google Scholar 

  49. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994; 264: 382–388.

    Article  PubMed  CAS  Google Scholar 

  50. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother 1992; 36: 695–703.

    Article  PubMed  CAS  Google Scholar 

  51. White NJ. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother 1992; 30: 571–585.

    Article  PubMed  CAS  Google Scholar 

  52. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375–382.

    Article  PubMed  CAS  Google Scholar 

  53. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med 1996; 335: 1445–1453.

    Article  PubMed  CAS  Google Scholar 

  54. Rattan A, Kalia A, Ahmad N Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis 1998; 4: 195–209.

    Article  PubMed  CAS  Google Scholar 

  55. Hall RM. Mobile gene cassettes and integrons: moving antibiotic resistance genes in gram-negative bacteria. Ciba Foundation Symposium 1997; 207:192–202; discussion 202–205.

    Google Scholar 

  56. Centers for Disease Control and Prevention. National antimicrobial resistance monitoring system: enteric bacteria, 1998 Annual Report. 1999; http://www.cdc.gov/ncidod/dbmd/narms.

  57. Glynn MK, Bopp C, Dewitt W, Dabney P, Mokhtar M, Angulo FJ. Emergence of multidrugresistant Salmonella enterica serotype typhimurium DT104 infections in the United States. N Engl J Med 1998; 338: 1333–1338.

    Article  PubMed  CAS  Google Scholar 

  58. Sandvang D, Aarestrup FM, Jenson LB. Characterisation of integrons and antibiotic resistance genes in Danish mulitresistant Salmonella enterica Typhimurium DT104. FEMS Microbiol Lett 1997; 157: 177–181.

    Article  PubMed  CAS  Google Scholar 

  59. Doern GV, Brueggemann A, Huynh H, Wingert E, Rhomberg P. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997–1998. Emerg Infect Dis 1999 5: 757–765.

    Article  PubMed  CAS  Google Scholar 

  60. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321: 1696–702.

    Article  PubMed  CAS  Google Scholar 

  61. Hall CB, Dolin R, Gala CL, Markovitz DM, Zhang YQ, Madore PH, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80: 275–282.

    PubMed  CAS  Google Scholar 

  62. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064–1073.

    Article  PubMed  CAS  Google Scholar 

  63. Jorgenson JH. Laboratory issues in the detection and reporting of antibacterial resistance. Infect Dis Clin North Am 1997; 11: 785–802.

    Article  Google Scholar 

  64. U.S. Congress Office of Technology Assessment. Impacts of antibiotic resistant bacteria. Washington, DC. U.S. Government Printing Office. 1995; OTA-H-29.

    Google Scholar 

  65. Ballard AL, Cane PA, Pillay D. HIV drug resistance: genotypic assays and their possible applications. Sex Transm Infect 1998; 74: 243–248.

    Article  PubMed  CAS  Google Scholar 

  66. Hirsch MS, Conway B, D’Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998; 279: 1984–1991.

    Article  PubMed  CAS  Google Scholar 

  67. Pillay D. Emergence and control of resistance to antiviral drugs in resistance in herpes viruses, hepatitis B viruses, and HIV. Commun Dis Publ Hlth 1998; 1: 5–13.

    CAS  Google Scholar 

  68. NCCLS. Performance standards for antimicrobial susceptibility testing; ninth informational supplement. NCCLS document number M100–S9 1999; 19: 1–104.

    Google Scholar 

  69. Dowell SF, Butler JC, Giebink GS, Jacobs MR, Jernigan D, Musher DM, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group: Pediatr Infect Dis J 1999; 18: 1–9.

    CAS  Google Scholar 

  70. Buehler JW, Surveillance. In: Buehler J W. Rothman KJ, Greenland S (eds). Modern Epidemiology, 2nd edit. Philadelphia: Lippincott-Raven, 1998, pp. 435–457.

    Google Scholar 

  71. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 1997; 46626–46630.

    Google Scholar 

  72. Fidler DP. Legal issues associated with antimicrobial drug resistance. Emerg Infect Dis 1998; 4: 169–177.

    Article  PubMed  CAS  Google Scholar 

  73. Dowell SF, Whitney CG, Schwartz B. Regional characteristics of drug-resistant respiratory pathogens. Series: New challenges in respiratory tract infections and causative pathogens. Part II: diagnostic perspectives and antibiotic-resistant bacteria in lower respiratory tract infections. ( Cohen, M.S., ed.) Am J Med Continuing Education Series 1997; 9–16.

    Google Scholar 

  74. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279: 1977–1983.

    Article  PubMed  CAS  Google Scholar 

  75. Perreten V, Schwarz F, Cresta L, Boeglin M, Dasen G, Teuber M. Antibiotic resistance spread in food. Nature 1997; 389: 801–802.

    Article  PubMed  CAS  Google Scholar 

  76. Witte W. Medical consequences of antibiotic use in agriculture. Science 1998; 279: 996–997.

    Article  PubMed  CAS  Google Scholar 

  77. Bates J. Epidemiology of vancomycin-resistant enterococci in the community and the relevance of farm animals to human infection. J Hosp Infect 1997; 37: 89–101.

    Article  PubMed  CAS  Google Scholar 

  78. Khachatourians GG. Agricultural use of antibiotics and the evolution and transfer of antibiotic-resistant bacteria. CMAJ 1998; 159: 1129–1136.

    PubMed  CAS  Google Scholar 

  79. Witte W. Impact of antibiotic use in animal feeding on resistance of bacterial pathogens in humans. Ciba Foundation Symposium; 207: 61–71; discussion 71–75.

    Google Scholar 

  80. Altekruse SF, Cohen ML, Swerdlow DL. Emerging foodborne diseases. Emer Infect Dis 1997; 3: 285–293.

    Article  CAS  Google Scholar 

  81. McKellar QA. Antimicrobial resistance: a veterinary perspective. Antimicrobials are important for animal welfare but need to be used prudently. Br Med J. 1998; 317: 610–611.

    Article  CAS  Google Scholar 

  82. Go ES, Urban C, Burns J, Kreisworth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymixin B and sulfbactam. Lancet 1994; 344: 1329–1332.

    Article  PubMed  CAS  Google Scholar 

  83. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA. Multiple antibiotic-resistant Klebsiella and Eschericia coli in nursing homes. JAMA 1999; 281: 517–523.

    Article  PubMed  CAS  Google Scholar 

  84. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999; 20: 303–316.

    Article  PubMed  CAS  Google Scholar 

  85. Garner J, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Am J Infect Control 1996; 24: 24–52.

    Article  PubMed  CAS  Google Scholar 

  86. Centers for Disease Control and Prevention. Guidelines for handwashing and hospital environmental control. MMWR 1988; 37.

    Google Scholar 

  87. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, et al. Strategies to prevent and control the emergence of spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996; 275: 234–240.

    Article  PubMed  CAS  Google Scholar 

  88. Levine OS, Farley M, Harrison L, Lefkowitz L, McGeer A, Schwartz B, Active Bacterial Core Surveillance Team. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 1999; 103: http://www.pediatrics.org/cgi/content/ful1/103–3/e28.

    Google Scholar 

  89. Dowell SF, Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am Fam Physician 1997; 55: 1647–1654.

    PubMed  CAS  Google Scholar 

  90. Chen FM, Breiman RF, Farley M, Plikaytis B, Deaver K, Cetron MS. Geocoding and linking data from population-based surveillance and the US census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections. Am J Epidemiol 1998; 148: 1212–1218.

    Article  PubMed  CAS  Google Scholar 

  91. Deeks SL, Palacio R, Ruvinsky R, Kertesz DA, Hortal M, Rossi A, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics 1999; 103: 409–413.

    Article  PubMed  CAS  Google Scholar 

  92. Arnold KE, Leggiadro RI, Breiman RF, Lipman HB, Schwartz B, Appleton MA, et al. Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee. J Pediatr 1999; 128: 757–764.

    Google Scholar 

  93. Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481–486.

    Article  PubMed  CAS  Google Scholar 

  94. Children in out-of-home child care. In: American Academy of Pediatrics, Peter G (eds). 1997 Red Book: Report of the Committee on Infectious Diseases, 24th edit. Elk Grove Village, IL: American Academy of Pediatrics, 1997, pp. 80–93.

    Google Scholar 

  95. School health. American Academy of Pediatrics, Peter G (eds). 1997 Red Book: Report of the Committee on Infectious Diseases, 24th edit. Elk Grove, IL: American Academy of Pediatrics, 1997, pp. 93–100.

    Google Scholar 

  96. Donowitz LG (ed). Infection control in the child care center and preschool, 3rd edit. Baltimore: Williams Wilkins, 1996.

    Google Scholar 

  97. American Public Health Association and American Academy of Pediatrics. Caring for our children. National health and safety performance standards: guidelines for out-of-home child care programs, Washington, DC: The Association, 1992.

    Google Scholar 

  98. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). JAMA 1996; 275: 206–216.

    Article  PubMed  CAS  Google Scholar 

  99. Gonzales R, Steiner JF, Lum A, Barrett PHJ. Decrease in antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 1999; 281: 1512–1519.

    Article  PubMed  CAS  Google Scholar 

  100. New class of antibiotics promising against gram-positive bacteria. Infect Dis Child 1999; May:65.

    Google Scholar 

  101. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995; 273: 214–219.

    Article  PubMed  CAS  Google Scholar 

  102. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997; 278: 901–904.

    Article  PubMed  CAS  Google Scholar 

  103. Mainous AG III, Hueston WJ, Clark JR. Antibiotics and upper respiratory infection: do some folks think there is a cure for the common cold? J Fam Pract 1996; 42: 357–361.

    PubMed  Google Scholar 

  104. Dowell SF, Schwartz B, Phillips WR, The Pediatric URI Consensus Team. Appropriate use of antibiotics for URIs in children: Part II. Cough, pharyngitis and the common cold. Am Fam Physician 1998; 58: 1335–1342.

    PubMed  CAS  Google Scholar 

  105. Calva J. Antibiotic use in a periurban community in Mexico: a household and drugstore survey. Soc Sci Med 1996; 42: 1121–1128.

    Article  PubMed  CAS  Google Scholar 

  106. Moellering RC. Vancomycin-resistant enterococci. Clin Infect Dis 1998; 26: 1196–1199.

    Article  PubMed  Google Scholar 

  107. Mulligan ME, Murray-Leisure KA, Ribner BS, Standiford HC, John JF, Korvick JA, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1999; 94: 313–328.

    Article  Google Scholar 

  108. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunne B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493–501.

    Article  PubMed  CAS  Google Scholar 

  109. Ross JDC. Fluoroquinolone resistance in gonorrhea: how, where and so what. Int J STD AIDS 1998; 9: 318–322.

    Article  PubMed  CAS  Google Scholar 

  110. Erbelding E, Quinn TC. The impact of antimicrobial resistance on the treatment of sexually transmitted diseases. Infect Dis Clin North Am 1997; 11: 889–903.

    Article  PubMed  CAS  Google Scholar 

  111. Ison CA. Antimicrobial agents and gonorrhoea: therapeutic choice, resistance, and susceptibility testing. Genitourin Med 1996; 72: 253–257.

    PubMed  CAS  Google Scholar 

  112. Division of STD Prevention. Sexually transmitted disease surveillance 1997 supplement: gonococcal isolate surveillance project (GISP) annual report-1997. Atlanta: U.S. Department of Health and Human Services, Public Health Service; Centers for Disease Control and Prevention. 1998; http://www.cdc.govincidod/dastIdgcdirkesist/gisp.html.

  113. Mermin JH, Townes JM, Gerber M, Dolan N, Mintz ED, Tauxe RV. Typhoid fever in the United States, 1985–1994: changing risks of international travel and increasing antimicrobial resistance. JAMA 1998; 158: 633–638.

    CAS  Google Scholar 

  114. Amyes SGB, Towner KJ. Trimethoprim resistance: epidemiology and molecular aspects. J Med Microbiol 1990; 31: 1–19.

    Article  Google Scholar 

  115. Mead P, Slutstker L, Dietz V, McCaig L, Bressee J, Shapiro C, et al. Food related illness and death in the United States. Emerg Infect Dis 1999; 5: 1–5.

    Article  Google Scholar 

  116. Quinn JP, Dudek EJ, DiVincenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa. J Infect Dis 1986; 154: 289–294.

    Article  PubMed  CAS  Google Scholar 

  117. Hancock REW. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27 (Suppl 1): S93 - S99.

    Article  PubMed  CAS  Google Scholar 

  118. Hodinka RL. What clinicians need to know about antiviral drugs and viral resistance. Infect Dis Clin North Am 1997; 11: 945–967.

    Article  PubMed  CAS  Google Scholar 

  119. Little S, Daar E, Keiser P, et al. The spectrum and frequency of reduced antiretroviral drug susceptibility with primary HIV infection in the United States [Abstract 121]. Antivir Ther 1999; 4 (Suppl 1): 86.

    Google Scholar 

  120. Wegner S, Brodine S, Mascola J, et al. High frequency of antiretroviral drug resistance in HIV-1 from recently infected therapy-naive individuals [Abstract 119]. Antivir Ther 1999; 4 (Suppl 1): 85.

    Google Scholar 

  121. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated with antiretroviral drug resistance among HIV-1 seroconverters in the United States, 1993–1998 [Abstract 143]. Antivir Ther 1999; 4 (Suppl 1): 99.

    Google Scholar 

  122. Ziegler T, Hemphill ML, Ziegler ML, Perez-Oronoz G, Klimov AI, Hampson AW, Regnery HL, Cox NJ. Low incidence of rimantidine resistance in field isolates of influenza A viruses. J Infect Dis 1999; 180: 935–939.

    Article  PubMed  CAS  Google Scholar 

  123. Laufer DS, Starr SE. Resistance to antivirals. Pediatr Clin North Am 1995; 42: 583–599.

    PubMed  CAS  Google Scholar 

  124. Reyes M, Subedar N, Graber JM, et al. Acyclovir-resistant herpes simplex virus pilot surveillance system. International Society for Antiviral Resistance, San Diego, April, 1998.

    Google Scholar 

  125. Bossche HV, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 (Suppl 1): 119–128.

    Google Scholar 

  126. Espinel-Ingroff A. Clinical relevance of antifungal resistance. Infect Dis Clin North Am 1997; 11: 929–944.

    Article  PubMed  CAS  Google Scholar 

  127. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 1291–1294.

    Article  PubMed  CAS  Google Scholar 

  128. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997; 24: 28–34.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Andrea L. Benin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott F. Dowell
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical University of South Carolina, Charleston, SC, USA

    Arch G. Mainous III PhD

  2. College of Medicine, University of Kentucky, Lexington, KY, USA

    Claire Pomeroy MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Benin, A.L., Dowell, S.F. (2001). Antibiotic Resistance and Implications for the Appropriate Use of Antimicrobial Agents. In: Mainous, A.G., Pomeroy, C. (eds) Management of Antimicrobials in Infectious Diseases. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-036-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-036-0_1

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5708-8

  • Online ISBN: 978-1-59259-036-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation